World’s First Personalized Ovarian Cancer Vaccine Trial Recruits Patients at UConn Health

World’s First Personalized Ovarian Cancer Vaccine Trial Recruits Patients at UConn Health
The University of Connecticut Health Center (UConn Health) is recruiting ovarian cancer patients for the world's first clinical trial testing a personalized genomics-driven vaccine (NCT02933073). The vaccine, called OncoImmunome, targets women with advanced stages of the disease to prevent its relapse. The vaccine boosts a patient's immune response, killing ovarian cancer cells should they reappear. The U.S. Food and Drug Administration approved UConn Health's human clinical trial after researchers — using animal models of ovarian cancer — showed the vaccine effectively reduced tumor growth. The study, to take place at UConn Health in Farmington will include 15 women with stage III or IV ovarian cancer at initial diagnosis or who suffered a first relapse. The enrolled patients will be monitored for two years, a period when the cancer is most likely to come back. In the trial, patients will undergo traditional surgery, during which doctors will collect and analyze a sample of the tumor to produce a personalized vaccine. Patients will first receive standard chemother
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *